Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has received an average recommendation of "Hold" from the sixteen analysts that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation, three have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $6.54.
A number of research analysts have issued reports on the stock. Cantor Fitzgerald raised shares of Editas Medicine from a "hold" rating to a "strong-buy" rating in a report on Tuesday. HC Wainwright started coverage on Editas Medicine in a research note on Monday, April 28th. They issued a "buy" rating and a $3.00 price objective for the company.
View Our Latest Research Report on EDIT
Institutional Trading of Editas Medicine
A number of hedge funds have recently bought and sold shares of EDIT. Barclays PLC boosted its holdings in shares of Editas Medicine by 46.9% during the third quarter. Barclays PLC now owns 178,507 shares of the company's stock worth $607,000 after purchasing an additional 56,986 shares during the last quarter. Green Alpha Advisors LLC boosted its stake in Editas Medicine by 157.6% in the 4th quarter. Green Alpha Advisors LLC now owns 111,628 shares of the company's stock worth $142,000 after buying an additional 68,295 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its holdings in Editas Medicine by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 267,758 shares of the company's stock valued at $340,000 after buying an additional 41,002 shares during the period. Thrive Wealth Management LLC acquired a new position in shares of Editas Medicine during the 4th quarter valued at about $36,000. Finally, SG Americas Securities LLC boosted its position in shares of Editas Medicine by 103.7% in the fourth quarter. SG Americas Securities LLC now owns 81,669 shares of the company's stock worth $104,000 after acquiring an additional 41,573 shares during the last quarter. Institutional investors and hedge funds own 71.90% of the company's stock.
Editas Medicine Trading Up 1.2 %
Shares of EDIT traded up $0.02 during mid-day trading on Monday, hitting $1.64. The company's stock had a trading volume of 1,874,744 shares, compared to its average volume of 2,579,963. Editas Medicine has a 1-year low of $0.91 and a 1-year high of $6.69. The firm has a market capitalization of $137.28 million, a P/E ratio of -0.64 and a beta of 2.14. The firm has a 50-day simple moving average of $1.42 and a 200 day simple moving average of $1.79.
Editas Medicine (NASDAQ:EDIT - Get Free Report) last issued its earnings results on Wednesday, March 5th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.16). Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. The company had revenue of $30.60 million for the quarter, compared to analysts' expectations of $37.17 million. During the same quarter in the previous year, the firm posted ($0.23) earnings per share. As a group, sell-side analysts predict that Editas Medicine will post -2.71 EPS for the current fiscal year.
Editas Medicine Company Profile
(
Get Free ReportEditas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
Featured Stories

Before you consider Editas Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Editas Medicine wasn't on the list.
While Editas Medicine currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.